Anti Inflammatory News and Research

RSS

Experts aim to relieve children from the side-effects of cancer treatments

Stopping children undergoing chemotherapy from feeling pain and other debilitating side-effects is the focus of research underway at The University of Queensland.

12 Aug 2022

Azelastine nasal spray could decrease SARS-CoV-2 load

A new study illustrated that early azelastine nasal spray therapy might lower the SARS-CoV-2 load among virus-infected patients.

11 Aug 2022

Interferon beta reduces binding of three components to RBCs, study finds

Drugs called interferon betas are common treatments for multiple sclerosis (MS), reducing relapses and slowing motor function decline. Interferon beta, a protein known to contain a zinc binding pocket, is thought to reduce proinflammatory molecules and even increase production of anti-inflammatory species in MS patients.

11 Aug 2022

How ultraprocessed foods affect gut microbiome and health

Researchers describe the association between the consumption of ultraprocessed foods and chronic medical conditions.

10 Aug 2022

Experimental drug protects mice from sudden death due to blood vessel rupture

An experimental drug therapy protects mice from sudden death due to the rupture of a major blood vessel in the abdomen, according to a study from researchers at Washington University School of Medicine in St. Louis.

10 Aug 2022

Researchers unravel a novel molecular target of eicosapentaenoic acid

Eicosapentaenoic acid (EPA) is an essential nutrient belonging to the omega-3 group of polyunsaturated fatty acids (PUFAs). As the human body cannot synthesize PUFAs, dietary supplements containing EPA are required for normal physiological functions. Found abundantly in natural sources like fish, hemp oil, and linseed oil, EPA is known to exhibit anti-inflammatory, neuroprotective, and cardiovascular protective activities.

9 Aug 2022

Inhaled aprotinin found to reduce viral load in mild-to-moderate COVID-19

A recent paper describes the use of aprotinin, a protease inhibitor that works across several pathways, to reduce the severity of COVID-19.

8 Aug 2022

Eating fish and seafood reduces risk of rheumatoid arthritis

Scientists determine the relationship between meat consumption and rheumatoid arthritis.

4 Aug 2022

Novel fusion protein drug for Alzheimer’s disease circumvents the neurotoxic inflammatory side effects

Although Aduhelm, a monoclonal antibody targeting amyloid beta (Aβ), recently became the first US FDA approved drug for Alzheimer's disease (AD) based on its ability to decrease Aβ plaque burden in AD patients, its effect on cognitive improvement is still controversial.

4 Aug 2022

Mice study reveals hepatic consequences of exposure to endocrine disrupting chemical mixtures

We are increasingly being exposed to endocrine-disrupting chemicals (EDCs) that interfere with the normal functioning of our hormones. Bisphenol A (BPA) and phthalates, which are widely used in consumer products including plastics, aluminum cans, pharmaceuticals, and cosmetics, are well-known EDCs.

4 Aug 2022

Gout flares associated with subsequent cardiovascular events

Experts at the University of Nottingham, in collaboration with experts at Keele University, have found that the risk of heart attacks and strokes temporarily increases in the four months after a gout flare.

2 Aug 2022

Study suggests peimine may be a potent inhibitor of SARS-CoV-2 variant infection

A recent study published in the Journal of Food Biochemistry discovered that peimine from Fritillaria might be a possible SARS-CoV-2 variant infection inhibitor.

2 Aug 2022

The efficacy of honokiol in inhibiting SARS-CoV-2 replication in cell culture

Researchers evaluated the efficacy of honokiol in inhibiting SARS-CoV-2 replication in cell cultures.

2 Aug 2022

The recent progress in investigating the inhibitory impact of nanosponges and antiviral delivery against SARS-CoV-2

Researchers assessed the potential of nanosponges against SARS-CoV-2.

1 Aug 2022

Routine periodic fasting associated with lower hospitalization risk in patients with COVID-19

The main objective of a new prospective observational cohort study was to evaluate whether periodic fasting is linked with severe COVID-19 symptoms.

1 Aug 2022

What is the immunopathogenesis of pediatric COVID-19?

Researchers assessed the immunopathogenesis of COVID-19 infection in children.

1 Aug 2022

Decoy ACE2 receptors broadly neutralize SARS-CoV-2 variants

Researchers review current developments in preclinical studies associated with recombinant ACE2 decoy receptors against coronaviruses.

31 Jul 2022

Is cannabidiol effective against COVID-19?

A new study discusses the utility of CBD in treating the inflammatory symptoms of COVID-19

31 Jul 2022

Study finds asymptomatic SARS-CoV-2 infection induced comparable memory B cell responses to mild symptomatic infection in young adults

Researchers identified that among healthy young adults, the development of SARS-CoV-2 triggered memory B cell and antibody reactions were equivalent following mildly symptomatic or asymptomatic infections.

29 Jul 2022

RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis

With this approval, RINVOQ® is the first and only Janus Kinase inhibitor approved to treat patients across the spectrum of axial spondyloarthritis (nr-axSpA and ankylosing spondylitis) in the EU.

From AbbVie 29 Jul 2022